Physician profile
Haley Waite
NPI 1528768116
$2,442.83
in general payments reported to CMS, 2019-2025
20 companies · $2,260 in 2025
The $2,260 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $183 · 2025: $2,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,109 · Education: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,108.86 |
| Education | $333.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $548.96 | 2024-2025 | Tremfya |
| Genzyme Corporation | $393.67 | 2025 | |
| Novartis Pharmaceuticals Corporation | $283.97 | 2025 | |
| Abbvie INC. | $222.71 | 2025 | |
| Sun Pharmaceutical Industries INC. | $212.06 | 2024-2025 | |
| Ucb, INC. | $182.90 | 2025 | Bimzelx |
| Sanofi-Aventis U.S. LLC | $99.00 | 2025 | |
| Lilly USA, LLC | $88.41 | 2024-2025 | Ebglyss, Taltz |
| Galderma Laboratories, L.P. | $77.33 | 2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $52.50 | 2025 | Zoryve |
| Incyte Corporation | $52.09 | 2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $39.74 | 2025 | Dupixent |
| Mayne Pharma Commercial LLC | $34.38 | 2025 | |
| Krystal Biotech INC | $33.94 | 2025 | Vyjuvek |
| Pfizer INC. | $27.31 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $22.90 | 2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.64 | 2025 | Spevigo |
| Biofrontera INC. | $18.93 | 2024 | Ameluz, Rhodoled Xl, Xepi |
| Amgen INC. | $17.52 | 2025 | Otezla |
| Leo Pharma INC. | $14.87 | 2024 | Adbry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Waite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.